ABSTRACT
Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy with a dismal prognosis 1 ; thus, identification of novel effective therapies is clinically important for this aggressive disease. A recent breakthrough of anticancer immunotherapy aimed at blocking the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway has shown clinical success for the treatment of a variety of cancers, including non-small cell lung cancer, melanoma, renal cell carcinoma, bladder cancer, and Hodgkin lymphoma. [2] [3] [4] [5] [6] [7] [8] Unfortunately, PDAs have shown only limited response to this therapy. 6, 9, 10 PD-1/PD-L1 plays a critical role in tumor immunity. PD-1 is expressed on activated T cells, B cells, and monocytes, and its expression is upregulated by cytokines such as interleukin (IL)-12 and interferon-γ. [11] [12] [13] PD-L1 is the primary ligand for PD-1, which helps to regulate peripheral tolerance and protect against autoimmunity by providing inhibitory signals to cytotoxic T cells. PD-L1 has been shown to be expressed on T cells, B cells, macrophages, dendritic cells, endothelial cells, and tumor cells. 12 It is thought that tumor cells can escape destruction by the host immune system by increasing their expression of PD-L1 (aka B7-H1). 12 Tumor cells and other cells in the tumor microenvironment that express high levels of PD-L1 can suppress immunity by interacting with PD-1 via many mechanisms, including T-cell apoptosis, functional exhaustion, and IL-10 production; mediating dendritic cell suppression; inducing differentiation of regulatory T cells; and protecting tumor cells from lysis by cytotoxic T lymphocytes. These mechanisms explain the clinical success observed
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Lehrke et al / PD-L1 ExPrEssion in UnDiffErEntiatED PancrEatic carcinoma using monoclonal antibodies against PD-1/PD-L1 for the treatment of some advanced-stage cancers. [4] [5] [6] 11, [14] [15] [16] [17] Expression of PD-L1 by tumor cells may be a predictive marker of response to anti-PD-1/PD-L1 therapies, but the data on this are not entirely consistent. 2, [6] [7] [8] 18 For example, in lung carcinoma, the correlation between objective treatment response rates and expression of PD-L1 by tumor cells ranges anywhere from 13% to 83%. 6, 14, 19 Also, some tumors that do not show expression of PD-L1 by tumor cells have also been reported to show significant responses, ranging from 3% to 20% of cases. 20, 21 In general, tumors that express PD-L1 tend to have an overall better response rate to PD-1/PD-L1 inhibition. 22 PD-L1 expression in PDAs has been described, with a reported positive rate ranging between 19% and 55%. [11] [12] [13] [23] [24] [25] [26] [27] In those studies, PD-L1 expression correlated with poor tumor differentiation, more advanced tumor stage, and worse prognosis than PD-L1-negative PDAs. Thus far, anti-PD1/PD-L1 treatment for unselected PDAs has not shown the favorable clinical response seen in some other cancers, 6,9,10 even though mouse model studies of PDAs show improved overall survival with anti-PD-1/αCD40 combination therapy. 11 In an extensive clinical study evaluating the effect of anti-PD-L1 therapy in 207 patients with cancer, 14 patients with unselected PDAs were treated with anti-PD-L1 therapy for a median duration of 12 weeks. None of the patients with PDA showed an objective response to PD-L1 inhibition, in contrast to a subset of patients with melanoma, renal cell carcinoma, non-small cell lung cancer, and ovarian cancer who did show an objective clinical response. 6 The refractoriness of PDA to PD-1/PD-L1 inhibition may be explained by the hypothesis that the tumor microenvironment in PDAs lacks high levels of activated natural killer cells, cytotoxic T cells, and effector T cells; instead, it is enriched for immunosuppressive leukocytes, such as tumor-associated macrophages, which express PD-L1. 28, 29 A second hypothesis for the refractoriness of PDA to PD-1/PD-L1 inhibition is that the clinical trials thus far have used PDAs that are unselected for grade and the extent of PD-L1 expression. It is possible that identifying PDAs with higher levels of PD-1/PD-L1 expression may identify a subset of PDAs that could potentially benefit from PD-1/PD-L1 blockade.
Undifferentiated pancreatic carcinoma (UPC) is a rare variant of PDA with a poor prognosis. These carcinomas are commonly heterogeneous and may show only very focal areas of ductal differentiation. They have been known under a variety of appellations, such as anaplastic carcinoma, sarcomatoid carcinoma, spindle cell carcinoma, pleomorphic carcinoma, pleomorphic giant cell carcinoma, and osteoclastic or pleomorphic giant cell tumor. [30] [31] [32] Although it has been shown that poorly differentiated PDAs tend to express PD-L1, little is known about PD-L1 expression in this unique type of pancreatic cancer. In this study, we performed immunohistochemical analysis of PD-L1 expression in a large series of UPCs and conventional PDAs in an attempt to compare PD-L1 expression and clinicopathologic features in the two groups of tumors.
Materials and Methods

Study Cases
Twenty-four UPCs and 48 conventional PDAs were identified in surgical pathology files at Mayo Clinic Rochester and Scottsdale from 1991 to 2016. All cases were histologically confirmed and showed keratin expression in the neoplastic cells. Among 24 UPCs, 16 cases were pleomorphic large cell predominant, five cases contained osteoclast-like giant cells, five cases possessed rhabdoid features, and one case was spindle-cell predominant. The 48 conventional PDAs included 14 well-differentiated, 13 moderately differentiated, and 13 poorly differentiated tumors, as well as eight tumors following neoadjuvant therapy (four moderate and four poorly differentiated). The institutional review board of Mayo Clinic approved this study.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tumor specimens. Briefly, 4-μm-thick tissue sections were stained using the Ventana BenchMark XT (Ventana Medical Systems, Tucson, AZ) automated slide-staining system. The staining protocol consisted of deparaffinization using EZ Prep, antigen retrieval for 30 minutes using Cell Conditioner 1 (Tris-EDTAbased buffer, Ventana Medical Systems), and incubation with primary antibodies at 37°C. The following antibodies were used in this study: anti-PD-L1 (clone E1L3N; Cell Signaling Technology, Beverly, MA), CD3 (clone LN10; Leica Biosystems, Newcastle, UK), CD20 (clone L26; Dako, Glostrup, Denmark), CD68 (clone PG-M1; Dako), MLH1 (clone G168-728; Cell Marque, Rocklin, CA), MSH2 (clone FE11; Biocare Medical, Concord, CA), MSH6 (clone BC/44; Biocare Medical), PMS2 (clone A16-4; Biocare Medical), and SMARCB1 (also known as INI-1) (clone 25/BAF47; BD Transduction Laboratories, San Jose, CA). Antigen-antibody reactions were visualized using UltraView (Ventana Medical Systems) detection with diaminobenzidine as the chromogen. The slides were counterstained with Hematoxylin II for 8 minutes followed by bluing reagent for 4 minutes. Stained slides were dehydrated and coverslipped in a xylene-based mounting medium.
Positive staining with anti-PD-L1 antibodies was defined as membranous expression. 33 PD-L1 expression in 1% or more tumor cells was considered positive, and the approximate percentage of positive cells over all tumors was recorded. Tumor-infiltrating CD3-positive T cells, CD20-positive B cells, and CD68-positive macrophages were counted in five areas with the densest staining and calculated as the average per one highpower field (hpf). The scores of all immunostains were evaluated independently by two pathologists (H.D.L. and L.Z.). The concordance between the two pathologists was generally good. A consensus of the percentage of positive cells was obtained if the discrepancy in a case was more than 5% between two readers. Tumors with absent nuclear staining of DNA mismatch repair enzymes (MLH1, MSH2, MSH6, or PMS2) represented microsatellite-instable tumors. Tumors that exhibited loss of nuclear staining with INI-1 were considered to represent rhabdoid UPC.
Statistical Analysis
Fisher exact test and the Student t test were performed to compare immunohistochemical results according to the pathologic variants. Overall survival was calculated from the date of surgery to the last follow-up date or date of recorded death. Overall survival was estimated using the Kaplan-Meier method and was compared with likelihood ratio tests from Cox proportional hazards regression. P values less than .05 were considered statistically significant. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
Results
Comparison of PD-L1 Expression in UPC and
Conventional PDA PD-L1 expression in UPC and PDA is summarized in ❚Table 1❚. Positive staining in tumor cells was significantly more frequent in UPC (15/24) than in conventional PDA controls (7/48) (63% vs 15%; P < .05) ❚Image 1❚. Among the conventional PDAs that expressed PD-L1, five of seven cases were poorly differentiated, one case was well differentiated, and one case was following neoadjuvant treatment. Four of five UPCs with osteoclast-like giant cells expressed PD-L1. Among five UPCs with rhabdoid morphology on H&E sections, only one was confirmed as rhabdoid UPC by loss of INI-1 nuclear staining in this study; it did not express PD-L1. The one UPC with predominant spindle cell features showed strong and diffuse expression of PD-L1, with 80% tumor cells positive. Only one of eight PDAs following neoadjuvant therapy was positive for PD-L1. The frequency of PD-L1 positivity was not statistically different between PDAs following neoadjuvant therapy and PDAs without preoperative treatment (1/8 vs 6/40, P = 1.0).
The extent of PD-L1 expression in UPCs was also significantly higher than that of the conventional PDAs ❚Figure 1❚. The mean ± SD percentage of positive tumor cells in UPC was 33.1% ± 28.2%, which was significantly higher than that seen in conventional PDAs (9.3% ± 11.2%, P < .05). Only three (43%) of seven conventional PDAs expressing PD-L1 had 10% or more of positive tumor cells, compared with 13 (87%) of 15 UPCs with 10% or more positive tumor cells (P = .05).
Expression of PD-L1 in DNA Mismatch Repair-Deficient UPC and PDA Two UPCs and one conventional PDA showed loss of expression of MSH2 and MSH6. Loss of expression of MLH1 and PMS2 was not observed in any case. All three mismatch repair-deficient tumors were positive for PD-L1, with more than 10% positive tumor cells (Images 1G and 1H). Although the statistical analysis showed a significantly higher frequency of mismatch repair deficiency in UPCs than conventional PDAs (2/24 vs 1/48, P < .01), the frequency of mismatch repair deficiency in PD-L1-positive tumors was not significantly different between UPCs and PDAs (2/15 vs 1/7, P = 1.0). However, given the small case numbers of mismatch repair-deficient tumors in our series of pancreatic carcinomas, the significance of these findings was unknown. 
Tumor-Infiltrating Immune Cells in Tumor Microenvironment
The tumor-infiltrating immune cells were counted within the tumor areas in all cases after staining with CD3, CD20, and CD68. All cases showed tumor-infiltrating immune cells in wide ranges. The tumor-infiltrating immune cells were predominantly composed of CD3-positive T cells and CD68-positive macrophages. The average number of T cells was 60/hpf (range, 6-208) in UPCs and 76/hpf (range, 36-126) in PDAs, the average number of macrophages was 53/hpf (range, 6-112) in UPCs and 58/hpf (range, 15-88) in PDAs, and the average number of B cells was 5/hpf (range, 0-18) in UPCs and 7/hpf (range, 0-19) in PDAs. There were no statistical differences in tumor-infiltrating tumor cells between two groups.
For UPCs, the average number of T cells was 68/ hpf (range, 16-208) in PD-L1-positive tumors and 41/ hpf (range, 6-113) in PD-L1-negative tumors; the average number of macrophages was 52/hpf (range, 6-112) in PD-L1-positive tumors and 44/hpf (range, 6-110) in PD-L1-negative tumors. Although the numbers of T cells and macrophages in PD-L1-positive UPCs were higher than those in PD-L1-negative tumors, the differences were not statistically significant. Overall survival (OS) did not differ significantly between PDA and UPC (P = .79), nor did it differ significantly by PD-L1 result within each group. Among patients with PDA, the 5-year OS was 26.3% and 28.6% for PD-L1 negative and positive, respectively (P = .76). Among patients with UPC, the 5-year OS was 25.0% and 28.6% for PD-L1 negative and positive, respectively (P = .47) ❚Figure 2❚.
Discussion
UPCs are significantly enriched in PD-L1 expression, in frequency and extent, compared with conventional PDAs. Poorly differentiated conventional PDAs also tend to have increased frequency of PD-L1 expression in comparison to well-differentiated or moderately differentiated PDAs, although most express PD-L1 to a more limited extent than that of UPCs. Our data suggest that anti-PD-1/ PD-L1 agents may be a valuable therapeutic approach for this subset of pancreatic carcinoma. In contrast to some previously published studies, our study did not show a correlation between PD-L1 expression and OS, but our study was not designed to test that hypothesis, and the small number of UPC cases limits its power in that regard. PD-L1 expression in pancreatic carcinoma has been well documented, [11] [12] [13] [23] [24] [25] [26] [27] but the objective clinical response rate of patients with PDA who have been treated with PD-1/PD-L inhibition has so far been disappointing. 6, 9, 10 One reason for this observed refractoriness may be a low frequency and extent of PD-L1 expression in PDAs. Although the reported literature suggests that up to 55% of PDAs express PD-L1, [11] [12] [13] [23] [24] [25] [26] [27] we found only 15% of conventional PDAs expressed PD-L1, and over half of those had less than 10% total PD-L1-positive tumor cells. Some of these studies evaluated PD-L1 expression by messenger RNA analysis, which may include PD-L1 expression in nontumor cells such as tumor-infiltrating immune cells. An additional explanation for the discrepancies observed between earlier published studies and ours may be related to changing immunohistochemical techniques. At the current time, the best predictor of response to anti-PD-1/PD-L1 therapy appears to be expression of PD-L1 by tumor cells, 34 but there are at least four different diagnostic immunohistochemical assays, one for each of the currently available anti-PD-1/PD-L1 therapeutics, complicating the reproducibility and uniformity of testing and reporting results. The immunohistochemical antibodies are each different clones, produced by different commercial vendors that require their own testing platform. 22, 35 For example, the antibody Dako 28-8 clone is used for defining treatment with nivolumab, the Dako 22C3 for pembrolizumab, and the Roche Ventana SP142 for atezolizumab. 22, 36 Some of these assays focus only on scoring the expression of PD-L1 on tumor cells; others also score PD-L1 expression on tumor-infiltrating immune cells. In addition to these differences, the assays have different definitions of a positive PD-L1 result (≥1%, ≥5%, or ≥50% of cells). Finally, preanalytical variables (sample collection, processing, and storage) may affect the results and interpretation of PD-L1 tests. An additional difficulty and shortcoming of the PD-L1 immunohistochemical assay is the subjective nature of scoring PD-L1 expression, particularly when the expression is low, as seen in multiple cases in our study, a recognized limitation. The anti-PD-L1 antibody used in this study is the one used throughout our practice as the standard-ofcare test for detecting PD-L1 expression. [37] [38] [39] The limited expression of PD-L1 by conventional PDAs found in this study may explain the observed low efficacy of PD-1/PD-L1 therapy in patients with unselected PDA, as documented in previous clinical trials. The distinction between selected and unselected pancreatic carcinomas with regard to histologic grade/subtype may be important, as our study showed significant differences between PD-L1 expression in UPCs and conventional PDAs. Nearly two-thirds of UPCs were positive for PD-L1, in comparison to only 15% of conventional PDAs. In addition, most UPCs also had higher expression levels of PD-L1, with one case displaying up to 90% tumor cell reactivity. Even by saying this, whether UPCs with high PD-L1 expression would respond to anti-PD-1/ PD-L1 therapy cannot be demonstrated in the current study, and prospective studies may be warranted in the future. Another possible reason to explain the poor response rate of PDAs to anti-PD-1/PD-L1 therapy may be related to variation in tumor microenvironment. A recent study showed that different tumor types possess varying immune cell PD-L1 expression patterns and that clinical responses to nivolumab therapy were significantly associated with PD-L1 expression by both tumor cells and immune cells. 18 Other studies have shown that the expression of PD-L1 by tumor-infiltrating immune cells is associated with an objective clinical response; one such study analyzed the association of PD-L1 expression by infiltrating immune cells in pretreatment samples of different cancer types and found that the immune cell expression prior to treatment with atezolizumab correlated with an objective clinical response. 7 In our study, we found that most tumor-infiltrating immune cells were T cells and macrophages. However, only a few cases showed some PD-L1 expression in tumor-infiltrating immune cells. It may be that the lack of preexisting host immune response in pancreatic cancers contributes to the poor treatment response to anti-PD-1/PD-L1 therapy. Detailed studies investigating the tumor microenvironment of pancreatic cancer and its association with clinical response rates in the future would help us to understand the immunosuppressive microenvironment in pancreatic carcinoma.
Other limitations of this assay (and our study) include heterogeneity of expression of PD-L1 itself; the tumor may show a heterogeneous expression of PD-L1, and selection of a single block within a large tumor sample may not give the accurate assessment of the tumor's overall expression of PD-L1 in vivo. In addition, PD-L1 expression may be increased in vivo by other adjunctive therapies given to the patient over the course of treatment. PD-L1 expression is known to be increased by exposure to interferon-γ and IL-12; thus, it is possible that other cytokines and microenvironment signals secondary to other forms of treatment may alter the tumor microenvironment and therefore affect PD-L1 expression. [11] [12] [13] 22 DNA mismatch repair status has recently been proposed as a potential biomarker for the use of anti-PD-1/ PD-L1 therapy. A recent clinical trial revealed that treatment-refractory metastatic lesions from mismatch repairdeficient tumors had a higher objective response rate and progression-free survival rate than mismatch repair-proficient tumors. 40 It is theorized that mismatch repair-deficient tumors may show greater response to PD-1/PD-L1 blockade due to a specific tumor microenvironment, specifically the CD8-positive T-cell lymphocytic inflammatory response to mutation-associated neoantigens in mismatch repair-deficient tumors. 40 To further support the use of PD-1/PD-L1 blockade in mismatch repairdeficient tumors, a patient with mismatch repair-deficient high-grade urothelial carcinoma experienced complete remission following therapy with experimental anti-PD-L1 inhibitors MEDI4736 and MEDI0680. 41 Our novel finding that a small number (n = 3) of mismatch repair-deficient PDA and UPC cases also had high expression levels of PD-L1 (all three cases >10% tumor cell positivity) suggests a potential role for targeted anti-PD-1/PD-L1 therapy in this particular subset of patients with pancreatic cancer.
It is important to note that PD-L1 expression may not be the only predictive factor for PD-1/PD-L1 blockade therapy. Patients with PD-L1-negative tumors should not be automatically considered ineligible for this treatment. For example, a study investigating clinical responses to pembrolizumab therapy in patients with melanoma found that preexisting CD8-positive T-cell infiltration at the invasive tumor margin correlated with a significant response to anti-PD-1/PD-L1 therapy. 42 In addition, studies have shown that tumors that possess very high mutational burdens (demonstrated by whole-exome sequencing) reportedly showed clinical responses to immunologic checkpoint blockade. 43, 44 In this quickly evolving area, further investigation on both clinical and basic research arenas may provide more robust approaches for prediction of response to immune checkpoint inhibition.
In summary, our study demonstrated that UPC is enriched for PD-L1 expression in frequency and extent, relative to conventional PDA. This finding may suggest that anti-PD-1/PD-L1 agents represent a valuable therapeutic approach for this subset of pancreatic carcinoma. Prospectively, it would be useful to evaluate anti-PD-1/ PD-L1 agents in pancreatic carcinomas selected for this histologic type. The limited amount of PD-L1 expression in the tumor cells of conventional PDAs, along with the paucity of PD-L1-positive tumor-infiltrating immune cells, may help explain the heretofore observed poor clinical response to anti-PD-1/PD-L1 therapy.
